Alfacell entered into a collaboration with the West German Cancer Center at the University of Duisburg-Essen for the development, characterization, and large-scale production of a novel fusion protein for non-Hodgkin’s lymphoma. The fusion protein consists of Onconase® (ranpirnase) and a humanized anti-CD22 monoclonal antibody.

“This fusion protein and other new molecular forms of Onconase will specifically target tumor cell by attaching to antigens on the cell surface,” explains Susanna Rybak, Ph.D., a key Alfacell liaison for this project. “These antigens will specifically internalize Onconase, thereby increasing its tumor-killing ability.”

Previous articleInvitrogen and HUPO Partner to Define Standards for Proteomic Research
Next articleArchemix and Elan Collaborate to Discover Aptamer Therapeutics